CA2687979A1 — Sustained delivery formulations of risperidone compounds
Assigned to Indivior UK Ltd · Expires 2008-12-18 · 17y expired
What this patent protects
The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating delusional psychosis, s chizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion d isorder, Tourette syndrome, and autistic spectrum dis…
USPTO Abstract
The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating delusional psychosis, s chizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion d isorder, Tourette syndrome, and autistic spectrum disorders. The sustained r elease delivery system includes a flowable composition containing risperidon e, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injecte d into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic p olymer, an organic liquid, and risperidone, a metabolite, or a prodrug there of.
Drugs covered by this patent
- Risperdal (risperidone) · Johnson & Johnson (Janssen)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.